Park Nicollet Health Services has become the first health care system in Minnesota, and one of an elite group nationally, to require doctors to publicly disclose their financial relationships with drug and medical device companies.
This week's move by Park Nicollet is designed to allay concerns that these relationships -- often forged with thousands of dollars in free meals and travel, speakers' fees, royalties for inventions and professional consultation payments -- pose a conflict of interest by influencing doctors' treatment decisions. Drug and device companies defend the payments, saying doctors' expertise is needed to make their products better.
Typically, the relationships are invisible to patients, but now those treated at Park Nicollet can begin viewing the details at tinyurl.com/cy5frs.
"I think that transparency is a terrific disinfectant for any conflicts, things that would interfere in the trusting relationship that patients depend on from our physicians and care teams," said Dr. Samuel Carlson, Park Nicollet's chief medical officer.
Minnesota has been a trendsetter in physician disclosure, but Park Nicollet's move could accelerate that trend. A 1993 state law that requires pharmaceutical companies to disclose their relationships with Minnesota doctors is getting a fresh look from legislators, who might retool it to add medical device companies.
Meanwhile, a task force at the University of Minnesota's Medical School recently recommended that doctors, researchers and students publicly reveal their industry ties. Most other major clinic systems in the state, including Mayo Clinic and Fairview Health Services, have internal disclosure rules, but have not taken the step of public disclosure.
With more than 1,400 doctors and clinicians at Methodist Hospital in St. Louis Park and in its network of 25 clinics in the Twin Cities, Park Nicollet appears to be at the forefront of a national trend of financial disclosure in medicine.
"Relationships with industry are ubiquitous in all aspects of medicine, medical education and medical research," said Dr. Eric Campbell, an associate professor of health care policy at the Harvard Medical School. "There's not a single aspect of medicine today that is not touched by drug, device and biotechnology companies."